Binary clinical trial risk - single Phase 1/2 failure in lead programs could eliminate 70-80% of market value given concentrated pipeline around BRG1/BRM mechanism
Chromatin regulatory target class validation risk - mechanism is novel with limited clinical precedent, creating higher probability of unforeseen safety issues or lack of efficacy
Regulatory pathway uncertainty for first-in-class mechanism requiring extensive FDA dialogue on endpoints and trial design
Competitive pressure from larger oncology players (Roche, BMS, Merck) developing alternative epigenetic modulators with greater resources
Kura Oncology, Syndax Pharmaceuticals, and other epigenetic-focused biotechs competing for same patient populations and clinical trial sites
Large pharma in-house programs targeting adjacent chromatin regulatory mechanisms could establish superior efficacy or safety profiles
Academic research identifying alternative BRG1/BRM inhibitors that could be licensed by competitors with faster development timelines
Cash runway of approximately 2-3 years at current burn rate creates forced financing risk in weak market conditions
Negative equity position (ROE of 105.5% with negative book value) reflects accumulated deficit exceeding assets
Dilution risk from future equity raises - small market cap of $300M means meaningful capital needs require substantial shareholder dilution
No debt capacity or revenue generation ability to bridge funding gaps, making company entirely dependent on equity market access
StructuralCompetitiveBalance Sheet